FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892797083> ?p ?o ?g. }

• W2892797083 endingPage "27" @default.
• W2892797083 startingPage "20" @default.
• W2892797083 abstract "BACKGROUND Tranexamic acid (TXA) is used as a hemostatic adjunct for hemorrhage control in the injured patient and reduces early preventable death. However, the risk of venous thromboembolism (VTE) has been incompletely explored. Previous studies investigating the effect of TXA on VTE vary in their findings. We performed a propensity matched analysis to investigate the association between TXA and VTE following trauma, hypothesizing that TXA is an independent risk factor for VTE. METHODS This retrospective study queried trauma patients presenting to a single Level I trauma center from 2012 to 2016. Our primary outcome was composite pulmonary embolism or deep vein thrombosis. Mortality, transfusion, intensive care unit and hospital lengths of stay were secondary outcomes. Propensity matched mixed effects multivariate logistic regression was used to determine adjusted odds ratio (aOR) and 95% confidence intervals (95% CI) of TXA on outcomes of interest, adjusting for prespecified confounders. Competing risks regression assessed subdistribution hazard ratio of VTE after accounting for mortality. RESULTS Of 21,931 patients, 189 pairs were well matched across propensity score variables (standardized differences <0.2). Median Injury Severity Score was 19 (interquartile range, 12–27) and 14 (interquartile range, 8–22) in TXA and non-TXA groups, respectively ( p = 0.19). Tranexamic acid was associated with more than threefold increase in the odds of VTE (aOR, 3.3; 95% CI, 1.3–9.1; p = 0.02). Tranexamic acid was not significantly associated with survival (aOR, 0.86; 95% CI, 0.23–3.25; p = 0.83). Risk of VTE remained elevated in the TXA cohort despite accounting for mortality (subdistribution hazard ratio, 2.42; 95% CI, 1.11–5.29; p = 0.03). CONCLUSION Tranexamic acid may be an independent risk factor for VTE. Future investigation is needed to identify which patients benefit most from TXA, especially given the risks of this intervention to allow a more individualized treatment approach that maximizes benefits and mitigates potential harms. LEVEL OF EVIDENCE Therapeutic, level III." @default.
• W2892797083 created "2018-10-05" @default.
• W2892797083 creator A5003339679 @default.
• W2892797083 creator A5029058133 @default.
• W2892797083 creator A5029774861 @default.
• W2892797083 creator A5034765888 @default.
• W2892797083 creator A5035673544 @default.
• W2892797083 creator A5063900162 @default.
• W2892797083 creator A5067313142 @default.
• W2892797083 date "2019-01-01" @default.
• W2892797083 modified "2023-10-18" @default.
• W2892797083 title "Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism" @default.
• W2892797083 cites W1938385245 @default.
• W2892797083 cites W1975661906 @default.
• W2892797083 cites W1976511219 @default.
• W2892797083 cites W2018697676 @default.
• W2892797083 cites W2022586543 @default.
• W2892797083 cites W2024066122 @default.
• W2892797083 cites W2038354089 @default.
• W2892797083 cites W2056941295 @default.
• W2892797083 cites W2075182040 @default.
• W2892797083 cites W2076647667 @default.
• W2892797083 cites W2083139851 @default.
• W2892797083 cites W2111548427 @default.
• W2892797083 cites W2162249417 @default.
• W2892797083 cites W2168835273 @default.
• W2892797083 cites W2171109226 @default.
• W2892797083 cites W2319699130 @default.
• W2892797083 cites W2321628844 @default.
• W2892797083 cites W2355654874 @default.
• W2892797083 cites W2390102805 @default.
• W2892797083 cites W2462315700 @default.
• W2892797083 cites W2554695882 @default.
• W2892797083 cites W2590176329 @default.
• W2892797083 cites W2622230396 @default.
• W2892797083 cites W2754026083 @default.
• W2892797083 cites W2765694822 @default.
• W2892797083 cites W2766461791 @default.
• W2892797083 cites W2990773265 @default.
• W2892797083 doi "https://doi.org/10.1097/ta.0000000000002061" @default.
• W2892797083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30239375" @default.
• W2892797083 hasPublicationYear "2019" @default.
• W2892797083 type Work @default.
• W2892797083 sameAs 2892797083 @default.
• W2892797083 citedByCount "126" @default.
• W2892797083 countsByYear W28927970832019 @default.
• W2892797083 countsByYear W28927970832020 @default.
• W2892797083 countsByYear W28927970832021 @default.
• W2892797083 countsByYear W28927970832022 @default.
• W2892797083 countsByYear W28927970832023 @default.
• W2892797083 crossrefType "journal-article" @default.
• W2892797083 hasAuthorship W2892797083A5003339679 @default.
• W2892797083 hasAuthorship W2892797083A5029058133 @default.
• W2892797083 hasAuthorship W2892797083A5029774861 @default.
• W2892797083 hasAuthorship W2892797083A5034765888 @default.
• W2892797083 hasAuthorship W2892797083A5035673544 @default.
• W2892797083 hasAuthorship W2892797083A5063900162 @default.
• W2892797083 hasAuthorship W2892797083A5067313142 @default.
• W2892797083 hasConcept C119060515 @default.
• W2892797083 hasConcept C126322002 @default.
• W2892797083 hasConcept C141071460 @default.
• W2892797083 hasConcept C156957248 @default.
• W2892797083 hasConcept C167135981 @default.
• W2892797083 hasConcept C17923572 @default.
• W2892797083 hasConcept C207103383 @default.
• W2892797083 hasConcept C2776265017 @default.
• W2892797083 hasConcept C2779637338 @default.
• W2892797083 hasConcept C2780011451 @default.
• W2892797083 hasConcept C2780868729 @default.
• W2892797083 hasConcept C2991743468 @default.
• W2892797083 hasConcept C44249647 @default.
• W2892797083 hasConcept C71924100 @default.
• W2892797083 hasConcept C77350462 @default.
• W2892797083 hasConceptScore W2892797083C119060515 @default.
• W2892797083 hasConceptScore W2892797083C126322002 @default.
• W2892797083 hasConceptScore W2892797083C141071460 @default.
• W2892797083 hasConceptScore W2892797083C156957248 @default.
• W2892797083 hasConceptScore W2892797083C167135981 @default.
• W2892797083 hasConceptScore W2892797083C17923572 @default.
• W2892797083 hasConceptScore W2892797083C207103383 @default.
• W2892797083 hasConceptScore W2892797083C2776265017 @default.
• W2892797083 hasConceptScore W2892797083C2779637338 @default.
• W2892797083 hasConceptScore W2892797083C2780011451 @default.
• W2892797083 hasConceptScore W2892797083C2780868729 @default.
• W2892797083 hasConceptScore W2892797083C2991743468 @default.
• W2892797083 hasConceptScore W2892797083C44249647 @default.
• W2892797083 hasConceptScore W2892797083C71924100 @default.
• W2892797083 hasConceptScore W2892797083C77350462 @default.
• W2892797083 hasIssue "1" @default.
• W2892797083 hasLocation W28927970831 @default.
• W2892797083 hasLocation W28927970832 @default.
• W2892797083 hasOpenAccess W2892797083 @default.
• W2892797083 hasPrimaryLocation W28927970831 @default.
• W2892797083 hasRelatedWork W2062272588 @default.
• W2892797083 hasRelatedWork W2118188452 @default.
• W2892797083 hasRelatedWork W2197337485 @default.
• W2892797083 hasRelatedWork W2379972596 @default.
• W2892797083 hasRelatedWork W2411696557 @default.

• next